SAILONG PHARMACEUTSS

SAILONG PHARMACEUT

14.67CNYD
+3.60%
At close at 09:18 GMT
CNY
No trades
See on Supercharts

002898 fundamentals

Key facts

Market capitalization‪2.49 B‬CNY
Basic EPS (TTM)−0.20CNY
Founded2002
CEOChi Nong Cai
Websitesailong.cn
About

Sailong Pharmaceutical Group Co., Ltd. engages in the research, development, production, and marketing of pharmaceutical intermediates, raw materials, and preparations. It also offers related technical services. Its key products include thymofaxine for injection, argatroban injection and raw materials, tigecycline for injection and raw materials, monosialotetrahexose ganglioside sodium injection and raw materials, cerebroprotein hydrolysate for injection, milrinone injection, parecoxib sodium for injection and raw materials, tranexamic acid injection, clindamycin phosphate for injection, and pantoprazole sodium for injection. The company was founded by Nan Gui Cai on April 3, 2002 and is headquartered in Zhuhai, China.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪2.49 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Revenue to profit conversion
No data available
There's currently no revenue data to show for the selected period.

Dividends

Dividend yield, history and sustainability

No dividends
002898 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Financial position analysis
No data available
There's currently no assets and liabilities data to show.